PROPr score validated in patients of hemodialysis or kidney transplant in new Study

They conducted a secondary analysis of data collected in multicenter, cross-sectional studies of adults treated with kidney replacement therapy, recruited between April 2016 to March 2020 in Toronto, Canada. Socioeconomic and clinical variables included age, sex, diabetes, estimated Glomerular Filtration Rate (eGFR), serum albumin, hemoglobin, kidney replacement therapy and Charlson-comorbidity index

Construct validity was assessed through correlations between PROPr and SF-6D or EQ-5D-5L and associations between PROPr and other exposure variables. Health condition impact estimates (coefficients for health conditions compared to a referent category: e.g. dialysis vs kidney transplant) were calculated using multivariable linear regression.

Their findings supported the validity of PROPr among 524 patients who were undergoing hemodialysis or who had recently received kidney transplants.

"Up to 70% of patients with kidney failure experience persistent physical symptoms and emotional distress that substantially impair health-related quality of life. These concerns are under-reported, under-recognized and under-managed," said Dr. Mucsi. "Our results open the doors for the use of PROPr and PROMIS® tools in nephrology research and in the care of patients with kidney failure."

Reference:

The study titled, "Evaluation of PROMIS Preference Scoring System (PROPr) in Patients Undergoing Hemodialysis or Kidney Transplant," is published in the Clinical Journal of the American Society of Nephrology (CJASN).